Repetitive levosimendan treatment in the management of advanced heart failure.

Eur Heart J Suppl · 2018 · PMC6288643 · PMID 30555280

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

23 A greater proportion of levosimendan-treated patients needed dose reduction or interruption due to significant hypotension (SBP <80 mmHg; levosimendan, 15%; placebo, 9%), although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.